HomeUSAImperative Care Raises $260M in Series D Funding

Imperative Care Raises $260M in Series D Funding

-

Imperative Care

Imperative Care, Inc.. a Campbell CA-based company focused on developing a portfolio of innovative solutions to address stroke care, raised $260M in Series D funding.

The round was led by D1 Capital Partners L.P. with participation from HealthCor Investments LLC, Innovatus Capital Partners, LLC, Ally Bridge Group, Bain Capital Life Sciences, Ascension Ventures, Delos Capital, Rock Springs Capital, and Amed Ventures. In conjunction with the funding, James Rogers from D1 will join Imperative Care’s Board of Directors.

The company intends to use the funds for:

  • commercialization and development of a wide range of technologies in the broad continuum of stroke care,
  • creating a strategic network of wholly owned development subsidiaries in a number of areas of synergy.

Co-founded in 2015 by Dr. Nick Hopkins, a pioneer of endovascular neurointervention and former Chief Scientific Officer of Jacobs Institute, and Fred Khosravi, a medtech entrepreneur and innovator, Imperative Care is developing a portfolio of innovative solutions to address the vast and urgent unmet needs in stroke care. The company has 510(k) clearances from the U.S. Food and Drug Administration (FDA) for two product platforms:

  • a family of access catheters called Large Distal Platform (LDP) designed to facilitate smooth, consistent navigation into blood vessels of the brain and
  • the Zoom Aspiration System, a family of products designed to facilitate clot removal during ischemic stroke.

In connection with the financing, the company also announced that it has acquired Truvic Medical, Inc., a peripheral thrombectomy innovator, in a stock-for-stock transaction. Under this transaction, Truvic will operate as a wholly owned subsidiary of Imperative Care, retaining its founding leadership team (led by Mike Buck, CEO) and distinct brand identity.

The proceeds from the Series D financing will also be used to advance Truvic’s development and commercialization of novel technologies for the treatment of peripheral vascular disease.

FinSMEs

17/07/2021

THE DAILY NEWSLETTER - SIGNUP